Duke Immune Profiling Core (DIPC)

Overview

The Duke Immune Profiling Core (DIPC) is a Duke School of Medicine and Duke Cancer Center Institute Service Center whose academic home resides in the Department of Surgery. Our overarching mission, "To identify immunologic signatures that predict clinical outcomes," comprises two components. The first is a Service component in which DIPC provides comprehensive, highly standardized, state-of-the-art human immunologic profiling services in support of both intra- and extramural translational research endeavors, including Phase I/II clinical trials. The second DIPC component focuses on Discovery, and utilizes advanced, high-dimensional Core technologies and resources to stimulate novel translational research initiatives that will impact the existing "standard of medical care." With over 28 years of experience in flow cytometry and immune profiling, we are available to support a wide range of services, such as small-scale projects for generating pilot data extending through clinical trial testing. Additionally, our services extend to single-cell proteomics and multiplex immunoassays, study planning, performing experiments, data collection and analysis, and writing support.

• Biosample Processing and Biorepository

• Immune Phenotyping by Polychromatic Flow Cytometry

• Multiplex Immunoassays

• Chip-Based Single Cell Proteomics Assays (Isolight)

• Bioinformatics and Biostatistics

• Computer Stations for Data Analysis

^*External prices include a mandatory overhead charge.  Overhead for internal users is not shown but is taken from the indirect costs of their funding source.

^##Per Plate charge is a minimum base rate for single color.  Rate increases based on whether Investigator or DIPC provides consumables (ie plate, tips, etc), Red Cell lysing, Cell Permeabilization Buffers, and/or quantitation.

^$$BD FACSymphony A5 (X50) and BD A5 SE usage is charged by the hour with exception to the user that has a TOTAL acquisition time of 30 minutes or less. 

^$%A complete acquisition of 30 minutes or less will be charged $37.50 on the FACSSymphony A5 (X50) or $335.00 on the A5 SE, as approved by the SOM.

^{^^}Technician/Core Operator time is charged by the 0.5hr.  Any time between 1-30 minutes = 0.5hr, 31-60 minutes = 1hr.

^&&Cellular Stimulation is for 1 stimulation.  The costs include consumables and reagents except for the test antigen(s).  Technician time will be applied as listed above.

^!!Sample Isolation is for 1 sample isolation for CD45, CD4, CD8, etc cells.  The costs include consumables and reagents necessary for sample isolation with the exception of the specific isolation kit (ie CD45, CD4, CD8, etc) which must be purchased directly by the Researcher.  Technician time will be applied as listed above.

**PBMC, Lymph Node, Ascites, and Pleural Effusion Processing costs include all consumables and reagents. Technician time will be applied as listed above.

^%%Tumor and Biopsy Processing costs include all consumables and reagents including Tumor Dissociation Kit Enzymes. Technician time will be applied as listed above.

DIPC Leadership

• Kent J. Weinhold, PhD (Director)
• Lynn Lin, PhD (Bioinformatics & Biostatistics)

DIPC Staff

• Jennifer Enzor
• Victoria Little
• Preksha Patel
• Katelyn Steadman
• Erin Murray

Immune profiling for vaccine trials

• From a multimillion dollar grant from NIH, DIPC will assess the cellular immune responses of volunteers in a malaria vaccine trials through the Vaccine Trials Evaluation Unit (VTEU).
   

Immune profiling for cancer immunotherapy trials

1. Neoadjuvant ipilimumab therapy for non-small cell lung cancer (NSCLC); NCT01820754
2. Neoadjuvant Pembrolizumab therapy or non-small cell lung cancer; NCT02818920
3. Evaluation of nivolumab alone versus nivolumab + ipilimumab therapy for recurrent glioblastomas; NCT02017717
4. Treatment of urothelial cancers with pembrolizumab alone versus pembrolizumab + ACP196 (a BTK inhibitor); IND#124755
5. Evaluation of anti-tumor reactivities in the lymph node and PBMC of metastatic, castrate-resistant prostate cancer patientsbefore or after receiving treatment with sipuleucel-T; NCT02036918NCT02036918
6. A randomized trial of Pembrolizumab and radiotherapy verus radiotherapy in high-risk soft tissue sarcoma of the extremity; NCT03092323

Core Staff Contact

duke.ipc@dm.duke.edu
Jennifer Enzor: (919) 684-3315
Katelyn Steadman: (919) 684-3542

Surgical Oncology Research Facility (SORF)
915 South LaSalle Street Ext.
Room 120 / 122 / 124
Durham, NC 27710